Navigation Links
New Ovarian Cancer Drug Trial Under Way
Date:9/7/2007

Phenoxodiol could help women resistant to other medicines

FRIDAY, Sept. 7 (HealthDay News) -- Ovarian cancer patients whose cancer has become resistant to traditional chemotherapy can now log-on to a new Web site to learn about a trial of a new drug, phenoxodiol.

In previous studies, phenoxodiol has shown some success in helping traditional chemotherapies continue to fight cancer cells.

The Phase III study of phenoxodiol will take place at 30 sites in the United States, 26 sites in Europe and at least four sites in Australia.

The goal of the Web site, www.OVATUREtrial.com, is to inform ovarian cancer patients about the Ovarian Tumor Response (OVATURE) trial, which is actively recruiting patients. Women suffering with ovarian cancer can learn about the study, the medication and locations for them to participate.

The trial is studying the safety and effectiveness of the drug phenoxodiol when combined with weekly doses of the chemotherapy drug carboplatin. Phenoxodiol is believed to help chemotherapy drugs kill chemoresistant cancer cells by removing factors in the cells that block the killing action of chemotherapy. Phenoxodiol has not yet been approved for use by the U.S. Food and Drug Administration.

Women who enter the trial will be assigned to one of two courses of treatment. The first will receive weekly carboplatin and phenoxodiol. Patients in the other course will receive carboplatin and a placebo weekly. Patients and their doctors will not know which course of treatment they have been given.

Receiving carboplatin weekly instead of every two or three weeks has been shown to provide tumor response in some patients with recurrent ovarian cancer. The study will expand understanding of the safety and effectiveness of both phenoxodiol and weekly carboplatin.

Phenoxodiol has been shown to reverse resistance to standard chemotherapies in lab animals. In a prior Phase II clinical trial, the drug showed some success in reversing tumor progression when it was tested in combination with cisplatin or paclitaxel.

Ovarian cancer occurs in one out of every 69 women and is the fifth leading cause of cancer death in women, according to the Ovarian Cancer National Alliance. It can be treated if diagnosed early, but most ovarian cancers are caught at later stages. When diagnosed in an advanced stage, women have a 30 percent chance of surviving five years.

More information

To learn more about ovarian cancer, visit the Ovarian Cancer National Alliance.



-- Madeline Vann



SOURCE: OVATURE, press release, Aug. 30, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Ovarian cancer in relationship with Hormone therapy
2. Progestin protects against ovarian cancer
3. Inherited gene important in ovarian cancer
4. Blood test may identify ovarian cancer
5. Exercise lowers Risk of Ovarian Cancer
6. Screening device for ovarian cancer
7. Ethnic discrepancy in ovarian cancer
8. Associated scan for detecting ovarian cancer spread
9. Gene Mutation Causes Ovarian Failure
10. Ovarian Cancer Screening Questioned
11. Thawed Ovarian Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the ... “America On The Brink” is the creation of published author, William Nowers. Captain ... As a WWII veteran, he spent thirty years in the Navy. Following his ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa Mohebi, the Los ... article to the newly revamped Cosmetic Town journal section, featuring articles ... procedure known as Follicular Unit Extraction (FUE). , Dr. Mohebi says ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... ORLANDO, Fla. , Oct. 2, 2017  AllianceRx ... services company formed by Walgreens and pharmacy benefit manager ... of its new brand, which included the unveiling of ... Fla. , as well as at a few ... introduces the new brand to patients, some of whom ...
(Date:9/27/2017)... -- Commended for their devotion to personalized service, SMP Pharmacy Solutions ... in the South Florida Business Journal,s 50 Fastest-Growing Companies, and ... the national specialty pharmacy has found its niche.  To that ... be honored by SFBJ as the 2017 Power Leader in ... receive his award in October, Bardisa said of the three ...
Breaking Medicine Technology: